BZO-CHMOXIZID.

BZO-CHMOXIZID belongs to the OXIZID subclass of synthetic cannabinoid receptor agonists, built not on an indole or an indazole but on a 2-oxoindoline core bearing a hydrazone linkage and a benzamide head, with the cyclohexylmethyl tail attached to the oxindole nitrogen. In vitro, the molecule behaves as a full agonist at the CB1 receptor and a partial agonist at the CB2 receptor. In β-arrestin 2 recruitment, its potency is 84.6 nM at CB1 and 2.21 nM at CB2, making it the most potent of the five OXIZIDs compared in that work; a second laboratory measures a Ki affinity of around 0.07 µM and a potency of around 0.06 µM at CB1, with an efficacy of 95.6 % in the Gαi pathway and of 127 % in β-arrestin 2 translocation, referenced to AMB-FUBINACA. This full CB1 agonism is precisely what separates these molecules from THC, which is only a partial agonist. Potency nevertheless remains moderate compared with earlier generations of synthetic agonists, and Patel et al. (2024) suggest that this middling CB1 activity could correspond to a lower toxicity than that of the preceding series, a hypothesis unverified in the field. In mice, the substance fully reproduces the discriminative signal of THC and proves the most potent of the series on that criterion. No target outside CB1 and CB2 has been studied, no clinical trial exists, and human data are entirely lacking, on effects as on toxicity, tolerance and dependence.

Source

An entirely synthetic molecule, absent from cannabis as from any living organism: it can be found neither in a hemp flower nor in a cannabidiol product. Its appearance on the market in 2021 is linked to the Chinese regulation that came into force in July 2021, which banned at a stroke seven chemical skeletons of synthetic cannabinoid agonists, essentially indole- and indazole-based, without covering the oxindole core of the OXIZIDs; the CFSRE sees in it an apparent replacement of the banned skeletons by this family, which had remained outside the scope. The sample characterised in the United States in late 2021, submitted by a forensic laboratory in Indianapolis, was a plant-like material (CFSRE).

No biosynthetic pathway: the molecule is produced by no living organism. It comes from organic synthesis, described here by chemical class only.

European Union

No Union text placing BZO-CHMOXIZID under control has been found: the substance does not appear in the annex to Framework Decision 2004/757/JHA, which carries the European definition of a "drug" in criminal law and is supplemented only by delegated directive. The most recent one verified, Delegated Directive (EU) 2025/2062 of 14 October 2025, added only three cathinones. MDA-19, the lead compound of the subclass, was detected in Europe as early as 2016 according to the EMCDDA cited by Patel et al. (2024); control currently falls to the national law of each Member State, whose arrangements differ. At international level, the molecule appears in no schedule of the 1971 Convention on Psychotropic Substances (INCB Green List, 36th edition, 2025); it is listed by the UNODC Early Warning Advisory among the synthetic cannabinoid receptor agonists. The 2021 United States report noted that no OXIZID analogue was at that time listed in the federal schedules of the United States.

France

The molecule is not named in the decree of 22 February 1990 setting the list of substances classified as narcotics, and its skeleton falls under no generic clause of annex IV. The generic clause covering the tetrahydrocannabinols, their esters, ethers and salts, entered in annex III of the consolidated list since the decision of 6 February 2026, does not concern this molecule. Annex IV covers, besides entries by name, a dozen families of synthetic agonists defined by their chemical core: indol-3-yl methanones, indazol-3-yl methanones, naphthoylpyrroles, naphthylmethylindoles, naphthylideneindenes, cyclohexylphenols, indole-3-carboxylates, indazole-3-carboxylates, indole-3-carboxamides, indazole-3-carboxamides, pyrrolo[3,2-c]pyridine carboxamides and thiazolyl indoles, as well as the derivatives of the benzo[c]chromene ring since the decision of 22 May 2024. The 2-oxoindolin-3-ylidene-hydrazine core of BZO-CHMOXIZID corresponds to none of these definitions. The contrast with its immediate neighbours is stark: the ANSM decision of 22 May 2024, applicable from 3 June 2024, listed BZO-HEXOXIZID (MDA-19) and BZO-POXIZID by name, without mentioning BZO-CHMOXIZID, and the consolidated list updated on 16 February 2026 does not mention it. The situation is therefore that of an unscheduled substance, neither by name nor by a generic clause. This absence of classification describes a state of the law and not an absence of risk: the status may change with each update of the list.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

Family

Synthetic CB receptor agonist › New psychoactive substance

Class

OXIZID (N-alkylated isatin acylhydrazone, benzoyl head, cyclohexylmethyl tail)

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

BZO-CHMOXIZID (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

1. 1Deventer M. H. et al., Drug Testing and Analysis, 2022: CB1 and CB2 potency and efficacy of the five OXIZIDs, including BZO-CHMOXIZID (new tab)PMID 35560866
2. 2Diaz P et al., Journal of Medicinal Chemistry, 2008: series of N-alkylated isatin acylhydrazones, selective CB2 agonists (MDA-19); values for BZO-CHMOXIZID read in ChEMBL (CHEMBL514565) (new tab)PMID 18666769
3. 3Patel M. et al., European Journal of Pharmacology, 2024: pharmacological evaluation of the OXIZIDs, CB1 affinity, Gαi and β-arrestin 2 pathways, THC discrimination in the mouse (new tab)PMID 38561104
4. 4Watanabe S. et al., Journal of Analytical Toxicology, 2023: in vitro metabolic profile of the OXIZIDs on human microsomes and hepatocytes (new tab)PMID 36857377
5. 5Lee K. Z. H. et al., Clinical Chemistry, 2022: optimal urinary markers of BZO-CHMOXIZID and of three other OXIZIDs (in vitro profile, four authentic urines), enzymes CYP3A4, CYP3A5 and CYP2C9 (new tab)PMID 36175111
6. 6CFSRE, NPS Discovery: chemical characterisation report on BZO-CHMOXIZID, 18 November 2021 (sample received on 4 November 2021 from the Indianapolis laboratory, plant-like material, GC-MS and LC-QTOF, not scheduled in the United States in 11/2021) (new tab)
7. 7Palamar J. J. et al., Journal of Analytical Toxicology, 2024: five unintentional exposures to the ANALOGUE BZO-4en-POXIZID in New York, data for the analogue and not for BZO-CHMOXIZID (new tab)PMID 37952092
8. 8UNODC, early warning advisory: substance record BZO-CHMOXIZID (synthetic cannabinoid receptor agonists) (new tab)
9. 9ANSM, consolidated list of substances classified as narcotics, updated 16 February 2026 (Annex IV: BZO-HEXOXIZID and BZO-POXIZID named, BZO-CHMOXIZID absent; Annex III: tetrahydrocannabinols clause) (new tab)
10. 10ANSM, decision of 22 May 2024 applicable from 3 June 2024: listing of BZO-HEXOXIZID and BZO-POXIZID, without BZO-CHMOXIZID (new tab)
11. 11Commission Delegated Directive (EU) 2025/2062 of 14 October 2025 amending the annex to Framework Decision 2004/757/JHA (new tab)
12. 12INCB, Green List of psychotropic substances, 36th edition, 2025 (1971 Convention: no OXIZID) (new tab)

SMILES

O=C(C1=CC=CC=C1)N/N=C(C2=O)/C3=CC=CC=C3N2CC4CCCCC4

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.